TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9007129

Group type: EXPERIMENTAL
Intervention: Paclitaxel 185 mg/m2 and Carboplatin 350 mg/m2
Number of subjects: 24
Study: 1891611

Group type: EXPERIMENTAL
Intervention: Computer-assisted reinforcement of instruction
Number of subjects: 52

Group type: COMPARATOR
Intervention: Traditional instruction in avoidance measures (Control)
Number of subjects: 52
Study: 6671879

Group type: EXPERIMENTAL
Intervention: Motivation at 0 payment
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Motivation at 25 payment
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Motivation at 50 payment
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Task difficulty: decreasing
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Task difficulty: increasing
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Training duration: three days
Number of subjects: 65
Study: 29563072

Group type: EXPERIMENTAL
Intervention: TIMBER-K (Ketamine + TIMBER therapy)
Number of subjects: 20

Group type: COMPARATOR
Intervention: TIMBER-P (Placebo + TIMBER therapy)
Number of subjects: 20
Study: 27295296

Group type: EXPERIMENTAL
Intervention: Manual trigger point compression therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Manual sham therapy
Number of subjects: 12
Study: 24978857

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine with 3.75 μg antigen
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine with 7.5 μg antigen
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Nonadjuvanted vaccine with 15 μg antigen (for children 12-35 months only)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Booster dose of MF59-adjuvanted seasonal influenza vaccine
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 330
Study: 22629160

Group type: EXPERIMENTAL
Intervention: Continuous Labor Epidural Analgesia (CLEA)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Intermittent Labor Epidural Analgesia (ILEA)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Febrile group (temperature ≥ 38 °C)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Afebrile group (temperature < 38 °C)
Number of subjects: 92
Study: 19878450

Group type: EXPERIMENTAL
Intervention: Sleep (S)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Sleep Deprivation (SD)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Recovery Sleep
Number of subjects: 108
Study: 16706150

Group type: EXPERIMENTAL
Intervention: Polychromatic visible + IR polarized light (480‐3400 nm, 12 J/cm2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 14576376

Group type: EXPERIMENTAL
Intervention: Extended Stroke Unit Service (ESUS)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Ordinary Stroke Unit Service (OSUS)
Number of subjects: 320
Study: 10794804

Group type: EXPERIMENTAL
Intervention: Oral granisetron 1 mg twice daily
Number of subjects: 230

Group type: COMPARATOR
Intervention: Prochlorperazine 10 mg sustained release capsule twice daily
Number of subjects: 230
Study: 8989127

Group type: EXPERIMENTAL
Intervention: hBNP infusion (0.003, 0.01, 0.03, and 0.1 microgram/kg per minute)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: hBNP infusion
Number of subjects: 20
Study: 1295444

Group type: EXPERIMENTAL
Intervention: FPEPIR regimen (CDDP + 5-FU + 4'-epirubicin)
Number of subjects: 60

Group type: COMPARATOR
Intervention: FP regimen (CDDP + 5-FU)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FPEPIR regimen
Number of subjects: 60

Group type: COMPARATOR
Intervention: FP regimen
Number of subjects: 60
Study: 3881574

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 25 mg
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg
Number of subjects: 164

Group type: COMPARATOR
Intervention: Aspirin 650 mg
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 164
Study: 30249940

Group type: EXPERIMENTAL
Intervention: Combined treatment with atorvastatin and amlodipine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 68
Study: 31494531

Group type: EXPERIMENTAL
Intervention: Lung cancer patients
Number of subjects: 91

Group type: COMPARATOR
Intervention: Nonmalignant pulmonary diseases
Number of subjects: 91

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Diagnostic model
Number of subjects: 91
Study: 28411114

Group type: EXPERIMENTAL
Intervention: Plasma biologically active adrenomedullin (bio-ADM) on day 1 (median [Q1-Q3], 110 [59-198] pg/mL)
Number of subjects: 956

Group type: EXPERIMENTAL
Intervention: bio-ADM trajectory during the first week of treatment
Number of subjects: 956

Group type: EXPERIMENTAL
Intervention: Reduction of bio-ADM below 110 pg/mL at day 7
Number of subjects: 956

Group type: EXPERIMENTAL
Intervention: bio-ADM concentration increase (OR [95% CI], 1.9 [1.4-2.5]; P < .0001)
Number of subjects: 956
Study: 25627664

Group type: EXPERIMENTAL
Intervention: Financial incentives (up to £400 in shopping vouchers)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 612
Study: 22972239

Group type: EXPERIMENTAL
Intervention: Step frequency manipulation group (SFM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Free step frequency group (SFF)
Number of subjects: 24
Study: 21463150

Group type: EXPERIMENTAL
Intervention: Medical therapy plus CABG
Number of subjects: 1212

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 1212
Study: 20029506

Group type: EXPERIMENTAL
Intervention: Quercetin 1000 mg.day(‐1) for 3 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17003304

Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Profile (DSMP)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Diabetes Behavior Rating Scale (DBRS)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Comparison of DSMP and DBRS
Number of subjects: 146
Study: 15271194

Group type: EXPERIMENTAL
Intervention: Ciclopirox 1% shampoo
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Ciclopirox 0.3% shampoo
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Ciclopirox 0.1% shampoo
Number of subjects: 203

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 203
Study: 11053509

Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (200 mg ferrous sulfate)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Twice weekly iron supplementation (2 x 200 mg ferrous sulfate)
Number of subjects: 191
Study: 9008378

Group type: EXPERIMENTAL
Intervention: Groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individuals
Number of subjects: 0
Study: 8292312

Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Comparison group (no treatment)
Number of subjects: 16
Study: 2979209

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg, 6-hourly, n = 8)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ranitidine (50 mg, 6-hourly, n = 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment (placebo, n = 12)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment (gastric ulcer patients)
Number of subjects: 30
Study: 28594747

Group type: EXPERIMENTAL
Intervention: Self-gripping Progrip mesh
Number of subjects: 274

Group type: COMPARATOR
Intervention: Sutured polypropylene mesh (standard)
Number of subjects: 274
Study: 27566642

Group type: EXPERIMENTAL
Intervention: Telehealth intervention (up to 13 scripted encounters with healthcare advisors)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 641
Study: 25100538

Group type: EXPERIMENTAL
Intervention: Early ambulation group (EAG)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard treatment group (STG)
Number of subjects: 31
Study: 22243907

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention group
Number of subjects: 309

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 309
Study: 20139391

Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily
Number of subjects: 670

Group type: COMPARATOR
Intervention: Dasatinib 50 mg twice-daily
Number of subjects: 670

Group type: COMPARATOR
Intervention: Dasatinib 140 mg once-daily
Number of subjects: 670

Group type: COMPARATOR
Intervention: Dasatinib 70 mg twice-daily
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily for 6 months without complete cytogenetic response
Number of subjects: 670
Study: 18084015

Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg once daily subcutaneously up to 8 days
Number of subjects: 2867

Group type: COMPARATOR
Intervention: Usual care (placebo or unfractionated heparin)
Number of subjects: 2867

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 2867

Group type: EXPERIMENTAL
Intervention: Fondaparinux vs. placebo
Number of subjects: 2867

Group type: EXPERIMENTAL
Intervention: Fondaparinux vs. UF heparin infusion for 24-48 h
Number of subjects: 2867
Study: 16147905

Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg/d) at bed-time
Number of subjects: 100

Group type: COMPARATOR
Intervention: Valsartan (160 mg/d) upon awakening
Number of subjects: 100
Study: 12514271

Group type: EXPERIMENTAL
Intervention: HSAFA diet (high saturated fat diet; 38.4% E% from fat; P/S ratio = 0.14)
Number of subjects: 25

Group type: COMPARATOR
Intervention: LSAFA diet (low saturated fat diet; 19.7% E% from fat; P/S = 0.17)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: HUFA diet (high content of mono- and polyunsaturated fatty acids; 38.2% E% from fat; P/S = 1.9)
Number of subjects: 25

Group type: COMPARATOR
Intervention: LSAFA diet
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: HSAFA diet
Number of subjects: 25
Study: 10645371

Group type: EXPERIMENTAL
Intervention: High visuo-spatial working memory group
Number of subjects: 2

Group type: COMPARATOR
Intervention: Concurrent tasks (verbal, visual, spatial-sequential, spatial-simultaneous)
Number of subjects: 2
Study: 9032708

Group type: EXPERIMENTAL
Intervention: Hyperventilation Provocation Test (HVPT)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo Test (PT, isocapnic overbreathing)
Number of subjects: 155
Study: 1391736

Group type: EXPERIMENTAL
Intervention: Furazolidone (FZ) high dose, 2 week course
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Furazolidone (FZ)
Number of subjects: 0
Study: 6120711

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Practolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 16
Study: 31151239

Group type: EXPERIMENTAL
Intervention: Bilateral infraorbital and infratrochlear nerve block with 8 mL of 0.5% ropivacaine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Isotonic saline (Sham Block group)
Number of subjects: 66
Study: 28845935

Group type: EXPERIMENTAL
Intervention: L-carnitine fumarate (1 g), acetyl-L-carnitine (0.5 g) twice daily, clomiphene citrate (CC) 25 mg twice daily, antioxidant complex (vitamins A, E, C, selenium, zinc)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) 25 mg twice daily, antioxidant complex (vitamins)
Number of subjects: 173
Study: 25721007

Group type: EXPERIMENTAL
Intervention: MEND 2-4 intervention (n=104)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (n=97)
Number of subjects: 201
Study: 24874591

Group type: EXPERIMENTAL
Intervention: vildagliptin + metformin
Number of subjects: 167

Group type: COMPARATOR
Intervention: glimepiride + metformin
Number of subjects: 167
Study: 18718771

Group type: EXPERIMENTAL
Intervention: Standard saphenofemoral ligation (SSL)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Flush saphenofemoral ligation (FSL)
Number of subjects: 182
Study: 15155403

Group type: EXPERIMENTAL
Intervention: Ready-to-use food (RTUF)
Number of subjects: 282

Group type: COMPARATOR
Intervention: RTUF supplement
Number of subjects: 282

Group type: COMPARATOR
Intervention: Blended maize/soy flour
Number of subjects: 282

Group type: COMPARATOR
Intervention: Maize/soy flour and RTUF supplement
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: All children that reached WHZ >0
Number of subjects: 282
Study: 11381581

Group type: EXPERIMENTAL
Intervention: Flat design (n=20)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Concave design (n=20)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Concave design (n=25)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Posterior-stabilised design (n=22)
Number of subjects: 83

Group type: COMPARATOR
Intervention: All prosthetic designs
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Concave design
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: All implants
Number of subjects: 83
Study: 9220214

Group type: EXPERIMENTAL
Intervention: Buspirone 30 mg/d, administered twice a day (BID)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Buspirone 30 mg/d, administered three times a day (TID)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Buspirone 15 mg BID
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Buspirone 10 mg TID
Number of subjects: 120
Study: 8345495

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg) after 48 hours of abstention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo after 48 hours of abstention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg) after 12 hours of abstention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo after 12 hours of abstention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine and placebo phases
Number of subjects: 0
Study: 2822997

Group type: EXPERIMENTAL
Intervention: Polyvalent immunoglobulins or CMV-hyperimmunoglobulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunoglobulins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperimmunoglobulin against varicella zoster
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperimmunoglobulins against pseudomonas aeruginosa
Number of subjects: 0
Study: 11557910

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Erythromycin (500 mg)
Number of subjects: 20
Study: 30478716

Group type: EXPERIMENTAL
Intervention: Microdose LSD (5, 10, and 20 μg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30203028

Group type: EXPERIMENTAL
Intervention: Immunonutrition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27814867

Group type: EXPERIMENTAL
Intervention: Kinesiology tape applied to quadriceps muscle
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no kinesiology tape)
Number of subjects: 30
Study: 24938502

Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch + physical exercises
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rivastigmine transdermal patch alone
Number of subjects: 40
Study: 22800889

Group type: EXPERIMENTAL
Intervention: Adenosine 50 µg×kg(‐1)×min(‐1) (low-dose group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Adenosine 70 µg×kg(‐1)×min(‐1) (high-dose group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline 1 ml/min (control group)
Number of subjects: 90
Study: 20625015

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Number of subjects: 217

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 217
Study: 17698695

Group type: EXPERIMENTAL
Intervention: BHT‐3009 (0.5 mg, 1.5 mg, and 3 mg) administered as intramuscular injections at weeks 1, 3, 5, and 9
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BHT‐3009 with 80 mg of daily oral atorvastatin calcium
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15647704

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive‐behavioral therapy
Number of subjects: 0
Study: 12401614

Group type: COMPARATOR
Intervention: Lidocaine 1% (2 mL)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Metoclopramide (10 mg, 2 mL)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo (2 mL)
Number of subjects: 159
Study: 10363691

Group type: EXPERIMENTAL
Intervention: N/R‐ATS (rabbit polyclonal antithymocyte serum)
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: OKT3
Number of subjects: 465

Group type: COMPARATOR
Intervention: No induction (no antithymocyte antibodies)
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: N/R‐ATS centers
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: OKT3 centers
Number of subjects: 465

Group type: COMPARATOR
Intervention: No IND centers
Number of subjects: 465
Study: 7480517

Group type: EXPERIMENTAL
Intervention: 0 cigarettes smoked prior
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2 cigarettes smoked prior
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5 cigarettes smoked prior
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 11 cigarettes smoked prior
Number of subjects: 10

Group type: COMPARATOR
Intervention: 6 hours of no smoking prior
Number of subjects: 10
Study: 2268438

Group type: EXPERIMENTAL
Intervention: Postoperative autologous blood transfusion (AT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no autologous transfusion)
Number of subjects: 20
Study: 7002427

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide combined with amiloride (AHCT)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Combination of timolol and AHCT
Number of subjects: 55

Group type: COMPARATOR
Intervention: AHCT
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Combination therapy (Timolol + AHCT)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Timolol and AHCT
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: PRA determination
Number of subjects: 55
Study: 30410041

Group type: EXPERIMENTAL
Intervention: TELE‐IBD EOW
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: TELE‐IBD Weekly
Number of subjects: 348

Group type: COMPARATOR
Intervention: Control
Number of subjects: 348
Study: 28992296

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan 100 mg (increased to 200 mg at week 4, and 400 mg at week 10 if BP >140/90 mm Hg)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (various doses as above)
Number of subjects: 588

Group type: COMPARATOR
Intervention: Olmesartan 10 mg (increased to 20 mg at week 4, and 40 mg at week 10 if BP >140/90 mm Hg)
Number of subjects: 588
Study: 25773405

Group type: EXPERIMENTAL
Intervention: Intensive management initiated within 1 week of diagnosis of type 1 diabetes
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: C-peptide
Number of subjects: 67
Study: 23721895

Group type: EXPERIMENTAL
Intervention: Arterial spin-labeling (ASL)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (age-matched cohort of 36 patients with no cerebrovascular events)
Number of subjects: 49
Study: 21545996

Group type: EXPERIMENTAL
Intervention: Standard anterior colporrhaphy
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Ultralateral colporrhaphy
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Anterior colporrhaphy plus polyglactin 910 mesh
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 114
Study: 19426116

Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapies targeting different pathways of T-cell activation
Number of subjects: 0
Study: 17539025

Group type: EXPERIMENTAL
Intervention: High HBV DNA levels prior to chemotherapy
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: High total bilirubin
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: HCV infection
Number of subjects: 188
Study: 15171772

Group type: EXPERIMENTAL
Intervention: Radiofrequency treatment on the left side of the face
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nontreated side (control)
Number of subjects: 10
Study: 11356768

Group type: EXPERIMENTAL
Intervention: Aspirin (1,300 mg) with water placebo (WP)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Aspirin (1,300 mg) with 6% CHO beverage
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Aspirin (1,300 mg) with 6% CHO+G beverage
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (P) with water placebo (WP)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (P) with 6% CHO beverage
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (P) with 6% CHO+G beverage
Number of subjects: 17
Study: 10806751

Group type: EXPERIMENTAL
Intervention: GnRH‐a 150 micrograms/day subcutaneously for three months
Number of subjects: 75

Group type: COMPARATOR
Intervention: mifepristone 12.5 mg/day po for three months
Number of subjects: 75
Study: 8283898

Group type: EXPERIMENTAL
Intervention: Heparin-coated extracorporeal circuit (Duraflo II)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Uncoated extracorporeal circuit
Number of subjects: 30
Study: 2743060

Group type: EXPERIMENTAL
Intervention: Experimental attention-training programme
Number of subjects: 20

Group type: COMPARATOR
Intervention: Attention-placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 20
Study: 29582411

Group type: EXPERIMENTAL
Intervention: modified natural cycle frozen-thawed embryo transfer (mNC-FET)
Number of subjects: 463
Study: 28821525

Group type: EXPERIMENTAL
Intervention: Washed allogeneic RBC transfusion
Number of subjects: 170

Group type: COMPARATOR
Intervention: Standard allogeneic RBC transfusion
Number of subjects: 170
Study: 26365268

Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancing interventions (structured discussion, testimonial video, reminder)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard physiotherapy and home-based pelvic floor muscle exercises
Number of subjects: 86

Group type: COMPARATOR
Intervention: Both groups (experimental and control)
Number of subjects: 86